Oncobiologics, Inc. Series B Warrant
ONSIZ
ONSIZ was delisted on the 16th of May, 2018.
13 hedge funds and large institutions have $918K invested in Oncobiologics, Inc. Series B Warrant in 2016 Q2 according to their latest regulatory filings, with 13 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$243K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$230K |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$219K |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$123K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$65.8K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PA
1
Perceptive Advisors
New York
| $202K | +$243K | +462,500 | New |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $196K | +$230K | +436,923 | New |
|
|
CAM
3
Cormorant Asset Management
Boston,
Massachusetts
| $187K | +$219K | +416,666 | New |
|
|
ACA
4
Avoro Capital Advisors
New York
| $105K | +$123K | +233,333 | New |
|
|
5
Marshall Wace
London,
United Kingdom
| $56K | +$65.8K | +125,100 | New |
|
|
PC
6
PointState Capital
New York
| $45K | +$52.6K | +100,000 | New |
|
|
ACP
7
Acuta Capital Partners
Redwood City,
California
| $44K | +$50.9K | +96,833 | New |
|
|
JG
8
Jefferies Group
New York
| $36K | +$41.7K | +79,347 | New |
|
9
Millennium Management
New York
| $20K | +$23.6K | +44,925 | New |
|
10
Hudson Bay Capital Management
Stamford,
Connecticut
| $14K | +$16.4K | +31,250 | New |
|
|
MIM
11
Monashee Investment Management
Boston,
Massachusetts
| $11K | – | – | – |
|
12
Morgan Stanley
New York
| $2K | +$3.07K | +5,830 | New |
|
|
TRCT
13
Tower Research Capital (TRC)
New York
| – | +$126 | +240 | New |
|
14
UBS Group
Zurich,
Switzerland
| – | +$395 | +750 | New |
|
ONSIZ Hedge Fund Activity: Q2 2016 in Review
13 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Oncobiologics, Inc. Series B Warrant (ONSIZ) for Q2 2016, worth a combined $918K.
Buyers outnumbered sellers: 13 funds opened new ONSIZ positions and 0 closed out — a net gain of 13 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $243K.
- 13 institutional investors held Oncobiologics, Inc. Series B Warrant (ONSIZ) as of Q2 2016, up from 0 in Q1 2016.
- Funds reported $918K of Oncobiologics, Inc. Series B Warrant stock for Q2 2016.
- 13 funds opened new Oncobiologics, Inc. Series B Warrant positions in Q2 2016 and 0 closed out, a net change of +13 holders.
- The largest Oncobiologics, Inc. Series B Warrant buyer in Q2 2016 was Perceptive Advisors, an estimated $243K added.
Based on aggregated 13F filings for Q2 2016.